Cinacalcet (Sensipar)
Cinacalcet hydrochloride (Sensipar - Amgen) has been approved by the FDA for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis and treatment of hypercalcemia in patients with parathyroid carcinoma....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Cinacalcet (Sensipar)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1192
Article Code: 1192c
Date: September 20, 2004
Volume: 46
Page: 80
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1192
Article Code: 1192c
Date: September 20, 2004
Volume: 46
Page: 80
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)